Nuformix Share Price. NFX - Stock Quote, Charts, Trade History, Share Chat, Financials. Nuformix Plc

Gold vs US Dollar

LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.

Home
Investing
Stocks
UK
LSE
Nuformix Plc (NFX)
Nuformix Plc (NFX) Share Price

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Nuformix Plc	LSE:NFX	London	Ordinary Share	GB00BYW79Y38	ORD 0.1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.025	11.36%	0.245	3,323,200	16:35:16

Bid Price		Offer Price	High Price	Low Price	Open Price
0.22		0.27	0.25	0.25	0.25

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceutical Preparations	0.05	-1.11	-0.20	-	1.74

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
14:36:32	O	1,639	0.22	GBX

Related Shares
Close Brothers (CBG), Paragon Banking (PAG), Boston (BIH), Davictus (DVT)

Nuformix (NFX) Latest News

Nuformix News

Date	Time	Source	Headline
02/6/2023	07:00	RNSNON	Nuformix PLC Investor Online Q&A
25/5/2023	07:00	UKREG	Nuformix PLC Change of Auditor
22/5/2023	12:45	ALNC	Nuformix loss narrows; near-term goal to focus on NXP002 asset
22/5/2023	07:00	UKREG	Nuformix PLC Unaudited Interim Report
18/5/2023	14:31	ALNC	TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect
18/5/2023	07:00	UKREG	Nuformix PLC NXP002 Inflammation and Duration of Action Update
26/4/2023	10:55	UKREG	Nuformix PLC Holding(s) in Company
17/4/2023	12:14	ALNC	Nuformix raises GBP70,000 to fund NXP002 programme
17/4/2023	07:00	UKREG	Nuformix PLC Subscription to raise GBP70,000 & issue of Warrants
27/3/2023	18:42	ALNC	TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

More Nuformix News

Nuformix Investors Nuformix Takeover Rumours

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date	Time	Title	Posts
01/6/2023	12:50	NUFORMIX September 2 Presentations - Massive Upside NFX	157
18/5/2023	07:08	Nuformix plc	9,116
28/1/2021	15:43	**NFX2021**	1

Add a New Thread

Nuformix (NFX) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
13:36:33	0.22	1,639	3.61	O
13:33:39	0.25	393,500	993.19	O
13:17:09	0.25	300,000	750.00	AT
13:17:02	0.25	276,032	690.08	O
12:34:01	0.23	41,990	94.94	O

View all Nuformix trades in real-time

Nuformix (NFX) Top Chat Posts

Top Posts
Posted at 18/5/2023 10:49 by institutional investments Price a good sign Tomorrow is the big day Kept down today for funds to get in Thursday/Friday be spectacular Read Full Thread Follow Reply
Posted at 18/5/2023 10:46 by dogsoggy36 100% it was not leaked,Never saw any results at all.Feel free to take a trip to the chat and see for yourself.Why has the price not moved is because Lanstead keep selling and 10% traders killed the momentum. Read Full Thread Follow Reply
Posted at 17/4/2023 21:52 by vaston Watch the mms have fun playing with the price tomorrow. Read Full Thread Follow Reply
Posted at 17/4/2023 08:07 by supercity Hilarious here - a 70k fund raise which is obviously to give a mate a stake in the company (the shares won't be sold) and the MMs drop the price.Don't knock a gift horse but the drop is total nonsense from sellers who have only read the headline - back level or positive within a few days or by the end of the day - mark my words Read Full Thread Follow Reply
Posted at 27/3/2023 07:29 by manual dexterity Nuformix PLC NXP002 Update 27/03/2023 7:00am UK Regulatory (RNS & others) Nuformix (LSE:NFX) Intraday Stock Chart Monday 27 March 2023 Click Here for more Nuformix Charts. TIDMNFX RNS Number : 2322U Nuformix PLC 27 March 2023 27 March 2023 Nuformix plc ("Nuformix" or the "Company" or the "Group") NXP002 Update Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the following update regarding the Company's NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF"). The Company recently announced the commencement of studies using a new iteration of a 3D human IPF lung tissue model - a high-challenge, disease and species relevant pre-clinical model with its partner, Fibrofind. Advancements within this model were designed to significantly reduce output variability. The Company has now received results from these studies of NXP002 alone and in combination with current standards of care ("SoC"), and they can be summarised as follows: -- NXP002 is well tolerated in ex-vivo human lung tissue with no signs of toxicity events; -- NXP002 alone delivers a strong, consistent anti-fibrotic effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis; -- Both high and low concentrations of NXP002 show an additive anti-fibrotic effect to SoC; -- In particular, the higher concentrations of NXP002 with SoC's deliver a near complete ablation of fibrosis biomarker release, yet at lower concentrations than have been seen in other pre-clinical models to date; and -- The clear, pronounced additive benefit of NXP002 on top of SoCs observed suggests that NXP002 will provide additional efficacy, even in patients responding to SoC therapy. This raises the possibility that NXP002 targets additional disease pathways to SoC's when increasing the combined anti-fibrotic response. Overall, the results provide further support of NXP002's potential to increase efficacy of existing therapies with the benefits of inhaled delivery (e.g. added efficacy without increased side effects). They also support NXP002's potential as a monotherapy for patients declining SoCs - a meaningful proportion of IPF patients who choose against the side effects of SoCs, which impact quality of life. Following the success achieved in these studies the Company's next steps include: -- Investigation of inflammation-related biomarkers in the same tissue sample sets to confirm additional mechanistic and anti-inflammatory benefits on top of SoC's, given the positive anti-fibrotic response; -- Expansion of the current study to include tissue from an additional two further human IPF tissue donors to demonstrate the robustness of NXP002's anti-fibrotic response alone and in SoC combinations in multiple patients; and -- To consider the expansion of the Company's on-going healthy lung tissue study investigating NXP002's duration of action to three donors, based on results when received. Understanding the performance of new IPF therapies with SoC's has become critical to both potential development partners and regulators. Therefore, the Company believes completion of these steps is required for Nuformix to secure the interest of out-licensing partners. Results will continue to be generated with further updates announced when appropriate . Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: " All parties are delighted with the results from this study, which are as good as we could have hoped for and are the first results from what is the most advanced iteration of this 'close to patient' IPF disease model to date. The reduced variability in the resulting data allows us to have high confidence in both NXP002's anti-fibrotic activity alone, but also in the added anti-fibrotic performance it can deliver on top of existing standards of care. Additivity to standard of care is the most important aspect because it's the simplest option to investigate in a clinical study and is therefore fast becoming a top priority for potential licensing partners. Having seen the quality of these results, our aim now is to generate datasets from three donors in both human IPF and healthy lung duration of action studies. These data can be generated quickly and will be essential in opening up new discussions with potential licensing partners and support overall progression of the NXP002 programme." Enquiries: Nuformix plc Dr Dan Gooding, Executive Director Via IFC Advisory Stanford Capital Partners Limited Tom Price / Patrick Claridge (Corporate Finance) +44 (0) 20 3650 3650 John Howes (Corporate Broking) +44 (0) 20 3650 3652 IFC Advisory Limited Tim Metcalfe +44 (0) 20 3934 6630 Zach Cohen nuformix@investor-focus.co.uk Read Full Thread Follow Reply
Posted at 20/6/2022 16:55 by pwhite73 The first sentence proves my very point. "The payment for the shares (£1.65m gross less legal fees) is paid to Nuformix but pledged to Lanstead" So the proceeds from the subscription is physically and financially paid to Nuformix. Nuformix then only "pledge" the money back to Lanstead depending on the share price. There is no shortfall in funds for Nuformix. If the share price is only 0.27p and the placing price was 1.5p it means NFX will only receive £300k of the £1.65m proceeds assuming the price does not drop further if Lanstead were holding the cash from the placings. As I said these RNSes are designed to trick you into thinking the death spiral funder has an interest in the progress of company. Its also important to note no further shares will be issued to make up for any shortfall in the share price. Read Full Thread Follow Reply
Posted at 20/6/2022 15:53 by soupdragon55 Pwhite, its a subscription with Lanstead based on the 1.5p shareprice. The £1.65m from this does not sit in NFX bank account. It sits in ESCROW, with an agreement that Lanstead release it each month. So if the share price is 50% lower than the benchmark, NFX only get a 50% payment that month. The rest goes back to Lanstead. Therefore Lanstead have paid less than the 1.5p benchmark. So if Lanstead dump all of their shares now and the price drops. They still have to pay each month, but will be paying a lot less and claiming back the difference. Therefore that would be market manipulation. So they can only sell stock they have paid NFX for. Read Full Thread Follow Reply
Posted at 20/12/2021 19:24 by sentiment riles Good morning, The Board is confident, following recent preclinical data in NXP002 and the strengthening of its IP portfolio around NXP004, that the near-term prospects for these products are strong, and will be further enhanced by additional pre-clinical development, including formulation work, toxicology studies, and preparations for Phase I trials, in addition to parallel business development work with potential partners. As the business strategy is executed, the Company is confident that this will be reflected by an increase in the share price, which will both increase the amount of money received by Nuformix in the Lanstead subscription, but also benefit Lanstead as the value of its investment will be higher. It is important to reiterate that Lanstead does not benefit from the share price declining, and they certainly do not ‘have control of the share price’ as you stated below – I am not sure what you mean when you refer to March 2020. As with any shareholder, Lanstead benefits when the share price appreciates. The Company spoke at length with Lanstead ahead of the subscription, and also spoke with executives from some of its other portfolio companies, which further underlined that Lanstead will be a supportive, long-term shareholder that has confidence in the Company’s ability to create value. If you have any further questions regarding the placing, there is a Q&A available on the Nuformix website:[...] Read Full Thread Follow Reply
Posted at 14/12/2021 17:53 by sentiment riles Lanstead Investment – Q&A Q. Why did Nuformix choose the Sharing Agreements with Lanstead? A: The sharing agreements with Lanstead allows Nuformix to benefit from positive share price performance over 20 months and the funding supports Nuformix’s activities over that period. We see a number of positive catalysts for Nuformix over the coming months, in particular as we make NXP004 Phase 1 ready and continue to strengthen the IP around NXP004, which should be positive for the share price as these are announced. Q: Is Lanstead entitled to invest monthly at a fixed discount to the prevailing Nuformix share price from month-to-month? A: No. Lanstead will be issued and will immediately pay for the shares it subscribes for at 1.5p per share. The number of shares issued to Lanstead is fixed and does not change. However, the amount from Lanstead due to the Company under the sharing agreements is adjustable upwards or downwards at each of the 20 monthly settlements that follow. For example; the approximate amount in any particular month will be 10% more than £82,500 if the share price is 10% higher than the 2.0p benchmark price (“BMP”) or 10% less than £82,500 if the share price is 10% lower than the BMP. Q: Can Lanstead benefit by the share price being lower than the 2.0p BMP, rather than going higher than 2.0p? A: No. Lanstead makes more money the higher the share price is. Through the sharing agreements Lanstead shares some, but not all, of the upside when the share price appreciates with Nuformix. The sharing agreements are an incentive for Nuformix to perform, thereby benefitting all shareholders including Lanstead. If the share price over 20 months averages double the BMP (i.e. 4.0p) then the Company will receive double the initial Lanstead subscription of £1.65 million (i.e. £3.30 million instead of £1.65 million). If the share price over 20 months averages half the BMP (i.e. 1.0p) then the Company will ultimately receive half the initial Lanstead subscription (i.e. £0.825 million instead of £1.65 million). The projected outcome for Nuformix is contractually clear and the value of Lanstead’s investment is greater if the company’s share price is higher. It is important to note that Lanstead participates in the majority, but not all of the upside in any future Nuformix share price appreciation. The bottom line is that Lanstead makes more money as the share price rises and does not derive any advantage from a decline in the share price. Q: Can Lanstead trade its Nuformix shares? A: Lanstead has a demonstrable track record of being a longer-term supportive shareholder to its investee companies. Like any institutional investor Lanstead only invests in companies where it can see strong potential for share price appreciation. Lanstead is free to buy and sell shares just like any other shareholder and it is required to disclose movements of >1% as a significant disclosable shareholder. Unlike other shareholders, Lanstead has an uncapped commitment through the sharing agreements to remit amounts each month to Nuformix based on the prevailing share price. Therefore whilst Lanstead may take a profit along the way (like any shareholder) and cover its downside risk on the investment (just like any shareholder), Lanstead also has an incentive (unlike other shareholders) to maintain a significant on-going shareholding because of its uncapped exposure on the amounts due to Nuformix over the 20 months of the sharing agreements should the Nuformix shares appreciate Read Full Thread Follow Reply
Posted at 21/10/2021 11:32 by inipvestor Nuformix PLC (LON: NFX) share price surged 12.7% despite the pharmaceutical company not making significant announcements today. Here's why.The lack of news from the company indicates that today's move higher was primarily driven by buying pressure from investors and positive sentiment. The last significant announcement from Nuformix was in September when it signed an exclusive licensing deal with Oxilio Ltd to develop and commercialise its cancer drug.While there is no direct trigger behind today's rally, we know that the one single driver behind a rallying share price is buying pressure.Therefore, we can confidently say that a wave of buying pressure has hit Nuformix share, triggering the rally.The buying pressure could be from a single institutional investor accumulating a significant position in the pharma company, or it could be from a group of investors with a bullish view of the stock.From a technical analysis standpoint, Nuformix shares have pushed back above the crucial 1.30p resistance level that could now act as support.However, we would need to see further gains before saying that the resistance level has turned into support. Currently, we could see the price fail to hold above the level leading to a further decline.Investors interested in opening new bullish positions in the stock should wait for the price to hold above the support zone and retest it before jumping in.People Who Read This Also ReadSensyne Health Share Price Trades Sideways Despite EU Regulatory ApprovalCeres Power Share Price Edged Higher After Appointing a New CFOPhoenix Copper Share Price Climbs As ADR's to Begin US Tr Read Full Thread Follow Reply

Nuformix share price data is direct from the London Stock Exchange

Your Recent History

LSE

NFX

Nuformix

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea

V: D: 20230605 17:53:26